Windward Bio Jumps 68% in Nasdaq Debut After $17 IPO Pricing
Windward Bio priced its Nasdaq IPO at $17.00 a share and closed its first day at $28.50, up 68%. See its asthma and COPD drugs and its backers.

Windward Bio, a clinical-stage biotech developing long-acting antibody drugs for asthma, COPD and atopic dermatitis, began trading on Nasdaq on Nov. 13 under the ticker WWB. The company priced its initial public offering at $17.00 per share, and the stock closed its first session at $28.50, a 68% gain over the offer price.
That closing price gave the company a market value of approximately $1.69 billion, according to a Nov. 14 press release from Qiming Venture Partners, one of its investors. The release did not say how many shares were sold or how much money the offering raised.
Who backed Windward Bio before the listing
Qiming put money into Windward’s first Series A round in 2025 and invested again in its Series B in 2026. The firm also bought into the IPO itself. Qiming said the listing is the 11th IPO among its portfolio companies in 2026.
Qiming was founded in 2006 and runs eleven US dollar funds and seven RMB (Chinese yuan) funds, with $9.5 billion in capital raised. It says it has backed more than 630 companies, and that over 290 of them have exited through listings on the NYSE, Nasdaq and exchanges in Hong Kong, Shanghai and Shenzhen, through acquisitions or by other routes.
What the company is developing
Windward was founded in 2024. Its drugs are biologics, meaning medicines made from proteins such as antibodies rather than chemical pills. The company is designing them to last a long time in the body, so patients would need fewer doses.
The lead drug, WIN378, is a monoclonal antibody that targets TSLP. It has been engineered to be more potent and to stay active longer. WIN378 is in two trials:
- POLARIS-1, a Phase 2/3 study in people with severe asthma that is not under control.
- SIRIUS, a Phase 2 study in chronic obstructive pulmonary disease (COPD).
A second drug, WIN027, is already in clinical testing. It is a bispecific antibody, built to hit two targets at once: TSLP and IL-13. The company sees possible uses for it across several inflammatory and immune diseases.
Where the drugs came from
Windward did not discover either drug itself. It licensed WIN378 from Kelun-Biotech and Harbour BioMed and holds exclusive worldwide rights to it, except in Greater China and certain other Asian countries. WIN027 came through a separate license from Qyuns Therapeutics.
What it means for shareholders and patients
New public shareholders now own part of a clinical-stage company whose drugs are still in trials. The release gave no timeline for data from POLARIS-1 or SIRIUS. For patients, the company’s stated aim is a lighter treatment burden and more options for serious respiratory and skin conditions, including atopic dermatitis.
A first-day jump like this one is set by how buyers and sellers meet when trading opens; our explainer on how the Nasdaq IPO cross sets the first trade walks through that process.
“Windward is well-positioned to deliver on this potential,” said Alexander Sinclair Wilson, a principal at Qiming, crediting Luca and his team. Qiming said it plans to keep supporting the company in its next phase.
Source: PR Newswire



